» Articles » PMID: 34120579

Prior Aerosol Infection with Lineage A SARS-CoV-2 Variant Protects Hamsters from Disease, but Not Reinfection with B.1.351 SARS-CoV-2 Variant

Overview
Date 2021 Jun 14
PMID 34120579
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The circulation of SARS-CoV-2 has resulted in the emergence of variants of concern (VOCs). It is currently unclear whether the previous infection with SARS-CoV-2 provides protection against reinfection with VOCs. Here, we show that low dose aerosol exposure to hCoV-19/human/USA/WA-CDC-WA1/2020 (WA1, lineage A), resulted in a productive mild infection. In contrast, a low dose of SARS-CoV-2 via fomites did not result in productive infection in the majority of exposed hamsters and these animals remained non-seroconverted. After recovery, hamsters were re-exposed to hCoV-19/South African/KRISP-K005325/2020 (VOC B.1.351) via an intranasal challenge. Seroconverted rechallenged animals did not lose weight and shed virus for three days. They had a little infectious virus and no pathology in the lungs. In contrast, shedding, weight loss and extensive pulmonary pathology caused by B.1.351 replication were observed in the non-seroconverted animals. The rechallenged seroconverted animals did not transmit the virus to naïve sentinels via direct contact transmission, in contrast to the non-seroconverted animals. Reinfection with B.1.351 triggered an anamnestic response that boosted not only neutralizing titres against lineage A, but also titres against B.1.351. Our results confirm that aerosol exposure is a more efficient infection route than fomite exposure. Furthermore, initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351 but prevents disease and onward transmission. These data suggest that previous SARS-CoV-2 exposure induces partial protective immunity. The reinfection generated a broadly neutralizing humoral response capable of effectively neutralizing B.1.351 while maintaining its ability to neutralize the virus to which the initial response was directed against.

Citing Articles

Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.

Wang S, Li W, Wang Z, Yang W, Li E, Xia X Signal Transduct Target Ther. 2024; 9(1):223.

PMID: 39256346 PMC: 11412324. DOI: 10.1038/s41392-024-01917-x.


Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters.

Darling T, Harastani H, Joshi A, Bricker T, Soudani N, Seehra K Sci Adv. 2024; 10(31):eadp1290.

PMID: 39083604 PMC: 11290484. DOI: 10.1126/sciadv.adp1290.


Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.

Port J, Yinda C, Riopelle J, Weishampel Z, Saturday T, Avanzato V Nat Commun. 2023; 14(1):6592.

PMID: 37852960 PMC: 10584863. DOI: 10.1038/s41467-023-42346-8.


Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2.

Francis M, Jansen E, Yourkowski A, Selim A, Swan C, MacPhee B Nat Commun. 2023; 14(1):5990.

PMID: 37752151 PMC: 10522707. DOI: 10.1038/s41467-023-41761-1.


The impact of primary immunization route on the outcome of infection with SARS-CoV-2 in a hamster model of COVID-19.

Barrett E, Revelli D, Bakshi C, Kadish A, Amar S Front Microbiol. 2023; 14:1212179.

PMID: 37293233 PMC: 10244709. DOI: 10.3389/fmicb.2023.1212179.


References
1.
Port J, Yinda C, Owusu I, Holbrook M, Fischer R, Bushmaker T . SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters. Nat Commun. 2021; 12(1):4985. PMC: 8371001. DOI: 10.1038/s41467-021-25156-8. View

2.
Tillett R, Sevinsky J, Hartley P, Kerwin H, Crawford N, Gorzalski A . Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020; 21(1):52-58. PMC: 7550103. DOI: 10.1016/S1473-3099(20)30764-7. View

3.
Wibmer C, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; 27(4):622-625. DOI: 10.1038/s41591-021-01285-x. View

4.
van Doremalen N, Falzarano D, Ying T, de Wit E, Bushmaker T, Feldmann F . Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res. 2017; 143:30-37. PMC: 6957253. DOI: 10.1016/j.antiviral.2017.03.025. View

5.
Rosenke K, Meade-White K, Letko M, Clancy C, Hansen F, Liu Y . Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerg Microbes Infect. 2020; 9(1):2673-2684. PMC: 7782266. DOI: 10.1080/22221751.2020.1858177. View